Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2004 March;43(1) > Minerva Pneumologica 2004 March;43(1):41-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Minerva Pneumologica 2004 March;43(1):41-50

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

Oral montelukast compared with inhaled salbutamol to prevent exercise-induced asthma in children

Macucci F., Guerrini L., Strambi M.


PDF


Aim. The aim of this paper was to evaluate the efficacy of montelukast, a leukotriene receptor antagonist, in preventing exercise-induced asthma (EIA), compared with salbutamol, currently considered as the first choice drug in this clinical condition.
Methods. Nine children (9-14 years-old) with mild-moderate asthma and a medical history of EIA and a fall in FEV1 >10% after exercise performed at a screening test. The exercise test, performed at the 1st consultation, was repeated in all subjects, preceded by the administration of inhaled salbutamol 15 min before the exercise test and after 4 weeks of treatment with montelukast administered in a single oral evening dose. The primary end point was the maximum percent fall in FEV1 (delta FEV1) from pre-exercise baseline value.
Results. The maximum percent fall in FEV1 from pre-exercise baseline found at the 1st consultation was significantly higher to that measured both after the administration of salbutamol (p<0.05) and after the treatment with montelukast (p<0.01). Both salbutamol and montelukast demonstrated to be able to prevent EIA (p=0.05 salbutamol vs base value, p=0.007 montelukast vs base value) without statistically significant differences (p=0.57).
Conclusion. Both of the drugs demonstrated to be effective in the prevention of EIA. The ease of consumption (orally) and the once daily dose of montelukast favoured therapeutic compliance.

top of page